Winway Health Desk
Viruses in the gut could kick-start type 1 diabetes development
Viruses that linger in the gut could potentially trigger type 1 diabetes in children, scientists have said.Research teams from the US and...
Congressman aims to break pharma’s insulin ‘pricing monopoly’ by legalizing Canadian...
U.S. legislators have been introducing bills left and right proposing a variety of methods for bringing down drug prices. Now, Vermont's congressman is zeroing in...
Covera Health raises $8.5M for analytics-based programs to reduce misdiagnoses
Covera Health, a startup offering analytics-based programs to reduce medical misdiagnoses, has raised $8.5 million in Series A financing.
Equity Group Investments led the round,...
It’s not a Brexit problem, Sanofi says of epilepsy drug shortages
Sanofi has restarted production at a plant where manufacturing had to be halted to fix pollution issues. The interruption created spot shortages of seizure drugs...
Xencor leukemia trial put on partial hold following two patient deaths
Two deaths in a clinical trial of a drug for acute myeloid leukemia have prompted the Food and Drug Administration to impose a partial...
FDA Approves Keytruda (pembrolizumab) for the Adjuvant Treatment of Patients with...
KENILWORTH, N.J.--(BUSINESS WIRE) February 19, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food...
Opting in just makes sense: The benefits of sharing medical data...
In the last decade, technology has progressed more than ever before, influencing nearly every aspect of our lives. One of the most important areas...
FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A
FDA Approves Esperoct (turoctocog alfa pegol, N8-GP) for Hemophilia A
Bagsværd, Denmark, 19 February 2019 - Novo Nordisk today announced that the US Food and...
Merck’s Keytruda flunks liver cancer confirmatory trial 3 months after accelerated...
One of the indications for Merck & Co.’s cancer immunotherapy drug could be under threat following the announcement Tuesday of negative results from a...
Teva, FTC enter expanded settlement barring certain ‘pay-for-delay’ deals for 10...
Teva has already had to pony up $1.2 billion to the federal government for a "pay-for-delay" deal to protect narcolepsy drug Provigil. But now...
